Research
Hormonal
In Type 2 Diabetes, the adoption of newer glucose-lowering medications (GLP-1 agonists and SGLT2 inhibitors) is associated with a significant decline in fracture incidence rates, particularly in men and women under 50 and over 70.
If you have Type 2 Diabetes, discuss with your doctor whether your current medication increases your fracture risk. The data suggests that switching to newer classes of drugs, specifically GLP-1 agonists or SGLT2 inhibitors, is associated with a significant reduction in fracture rates compared to older medications like sulfonylureas.
GoodSupportsHIGH confidence
The decline in the incidence of fractures in persons with T1D and T2D may be partly explained by... novel classes of glucose-lowering medications in T2D might have reduced fracture risk through better glycemic control. Like the trends of glucose-lowering medications shown in our study, the use of thiazolidinediones and sulfonylureas, associated with an increased fracture risk, has decreased substantially in persons with T2D in Denmark. Yet, the use of newer medications such as GLP-1 agonists and SGLT2 inhibitors, which have neutral or even beneficial effects on fracture risk, increased rapidly after their introduction.
Why this rating
Large-scale registry data (n>1M) with long-term observation, though observational and not RCT.
Source
Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes—A Systematic Review
Rikke Viggers et al. · JBMR Plus · 2023
DOI 10.1002/jbm4.10817
cohort · n=1235628Cited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →